The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Advances in controlled drug delivery to the sinonasal mucosa
Abstract
Controlled drug delivery is a valuable strategy for increasing local therapeutic concentrations in a sustained manner, particularly in locations that are difficult to access. One such target is the sinonasal mucosa, which can be chronically inflamed in patients with rhinitis or rhinosinusitis resulting in diminished quality of life, significant healthcare expenses, and multiple co-morbidities. While numerous medical therapies with daily administration are available, anatomical, physiological, and patient adherence barriers can limit their therapeutic efficacy. As such, there has been considerable development of biomaterial-based systems that can locally deliver anti-inflammatory, antibiotic, decongestant, and antihistamine medications over an extended duration. This review aims to highlight advances in such biomaterial-based systems for sinonasal delivery. Delivery vehicles including nasal packs, dressings, sinus stents, polymeric meshes, nanoparticles, microparticles, and in situ hydrogels are reviewed. Benefits of these vehicles are discussed, as well as their limitations, which, recently, has motivated the development of combination systems that leverage desirable properties of their individual components to enhance therapeutic delivery. Finally, discussion is provided on the potential of combination delivery vehicles, which can provide greater control of the duration of therapeutic release, as well as the ability to encapsulate multiple therapies, provide mechanical support, or conform to the mucosa. The future clinical use of controlled release systems with these attributes could have a transformative impact on improving treatment of difficult-to-control chronic diseases of the sinonasal mucosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These hydrogels exist in a liquid state at lower temperatures and transform into a three-dimensional polymeric network at body temperature, providing an opportunity for controlled therapeutic release in the sinonasal cavity [37,38,39].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis
Orlandi, R. R., Kingdom, T. T., Hwang, P. H., Smith, T. L., Alt, J. A., Baroody, F. M., Batra, P. S., Bernal‐Sprekelsen, M., Bhattacharyya, N., Chandra, R. K., et al. (2016) · International Forum of Allergy & Rhinology · doi:10.1002/alr.21695 · Cited by 892
High nitric oxide production in human paranasal sinuses
Lundberg, J. O. N., Farkas-Szallasi, T., Weitzberg, E., Rinder, J., Lidholm, J., Änggåard, A., Hökfelt, T., Lundberg, J. M., & Alving, K. (1995) · Nature Medicine · doi:10.1038/nm0495-370 · Cited by 628
Wheatley, L. M., & Togias, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1412282 · Cited by 606
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
Djupesland, P. G. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0108-9 · Cited by 563
Editors and Reviewers: Supporting Peer‐Review Publishing
Benninger, M. S. (2003) · Otolaryngology–Head and Neck Surgery · doi:10.1053/hn.2003.v128.amhn0312811 · Cited by 557
Research works printed but not linked: 156
- Bhattacharyya, 2011, Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States, Ann. Otol. Rhinol. Laryngol., 120, 423, 10.1177/000348941112000701 · DOI · Paper page
- Meltzer, 2011, The economic impact of allergic rhinitis and current guidelines for treatment, Ann. Allergy Asthma Immunol., 106, S12, 10.1016/j.anai.2010.10.014 · DOI · Paper page
- Sahin-Yilmaz, 2011, Anatomy and physiology of the upper airway, Proc. Am. Thorac. Soc., 8, 31, 10.1513/pats.201007-050RN · DOI · Paper page
- Jones, 2001, The nose and paranasal sinuses physiology and anatomy, Adv. Drug Deliv. Rev., 51, 5, 10.1016/S0169-409X(01)00172-7 · DOI · Paper page
- Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm., 532, 555, 10.1016/j.ijpharm.2017.09.018 · DOI · Paper page
- Gizurarson, 2015, The effect of cilia and the mucociliary clearance on successful drug delivery, Biol. Pharm. Bull., 38, 497, 10.1248/bpb.b14-00398 · DOI
- Schwab, 1998, Filtration of particulates in the human nose, Laryngoscope, 108, 120, 10.1097/00005537-199801000-00023 · doi:10.1097/00005537-199801000-00023
- Dalgorf, 2013, Sinonasal anatomy and function, Am. J. Rhinol. Allergy, 27, S3, 10.2500/ajra.2013.27.3888 · doi:10.2500/ajra.2013.27.3888
- Parikh, 2014, Drug-eluting nasal implants: formulation, characterization, clinical applications and challenges, Pharm. Times, 6, 249
- Keck, 2000, Temperature profile in the nasal cavity, Laryngoscope, 110, 651, 10.1097/00005537-200004000-00021 · DOI · Paper page
- Pinto, 2011, Olfaction, Proc. Am. Thorac. Soc., 8, 46, 10.1513/pats.201005-035RN · DOI
- Mygind, 1998, Anatomy, physiology and function of the nasal cavities in health and disease, Adv. Drug Deliv. Rev., 29, 3, 10.1016/S0169-409X(97)00058-6 · DOI · Paper page
- Lai, 2009, Micro- and macrorheology of mucus, Adv. Drug Deliv. Rev., 61, 86, 10.1016/j.addr.2008.09.012 · DOI · Paper page
- Cohen, 2006, Sinonasal mucociliary clearance in health and disease, Ann. Otol. Rhinol. Laryngol., 115, 20, 10.1177/00034894061150S904 · DOI · Paper page
- Laulajainen-Hongisto, 2020, Airway epithelial dynamics in allergy and related chronic inflammatory airway diseases, Front. Cell Dev. Biol., 8, 204, 10.3389/fcell.2020.00204 · DOI
- Fokkens, 2000, Upper airway defence mechanisms, Paediatr. Respir. Rev., 1, 336
- Conway, 2000, The nose and nitric oxide: a review, Clin. Otolaryngol., 25, 337, 10.1046/j.1365-2273.2000.00378.x · DOI
- Bogdan, 2001, Nitric oxide and the immune response, Nat. Immunol., 2, 907, 10.1038/ni1001-907 · DOI · Paper page
- Runer, 1998, Effects of nitric oxide on blood flow and mucociliary activity in the human nose, Ann. Otol. Rhinol. Laryngol., 107, 40, 10.1177/000348949810700108 · DOI
- Brożek, 2017, Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision, J. Allergy Clin. Immunol., 140, 950, 10.1016/j.jaci.2017.03.050 · DOI · Paper page
- Bousquet, 2008, Allergic rhinitis and its impact on asthma (ARIA) 2008, Allergy, 63, 8, 10.1111/j.1398-9995.2007.01620.x · DOI · Paper page
- Dykewicz, 2010, Rhinitis and sinusitis, J. Allergy Clin. Immunol., 125, S103, 10.1016/j.jaci.2009.12.989 · DOI · Paper page
- DeConde, 2016, Chronic rhinosinusitis: epidemiology and burden of disease, Am. J. Rhinol. Allergy, 30, 134, 10.2500/ajra.2016.30.4297 · DOI · Paper page
- Baroody, 2000, Antiallergic effects of H1-receptor antagonists, Allergy, 55, 17, 10.1034/j.1398-9995.2000.00803.x · DOI
- Rosenfeld, 2015, Clinical practice guideline (update): adult sinusitis, Otolaryngol. Head Neck Surg., 152, S1
- Snidvongs, 2017, Update on intranasal medications in rhinosinusitis, Curr. Allergy Asthma Rep., 17, 47, 10.1007/s11882-017-0720-3 · DOI
- Piromchai, 2013, Chronic rhinosinusitis and emerging treatment options, Int. J. Gen Med., 6, 453, 10.2147/IJGM.S29977 · DOI
- Schleimer, 2017, Immunopathogenesis of chronic rhinosinusitis and nasal polyposis, Annu. Rev. Pathol., 12, 331, 10.1146/annurev-pathol-052016-100401 · DOI · Paper page
- Fastenberg, 2016, Biofilms in chronic rhinosinusitis: pathophysiology and therapeutic strategies, World J. Otorhinol. Head Neck Surg., 2, 219, 10.1016/j.wjorl.2016.03.002 · DOI · Paper page
- Hulse, 2015, Immune mechanisms of chronic rhinosinusitis, Curr. Allergy Asthma Rep., 16, 1, 10.1007/s11882-015-0579-0 · DOI
- Lee, 2011, Chronic rhinosinusitis as a multifactorial inflammatory disorder, Curr. Infect. Dis. Rep., 13, 159, 10.1007/s11908-011-0166-z · DOI
- Sastre, 2012, Local and systemic safety of intranasal corticosteroids, J Investig. Allergol. Clin. Immunol., 22, 1
- Han, 2012, Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis, Int. Forum Allergy Rhinol., 2, 271, 10.1002/alr.21044 · DOI
- DeConde, 2017, Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis, Laryngoscope, 127, 550, 10.1002/lary.26391 · DOI · Paper page
- Mendelsohn, 2011, Revision rates after endoscopic sinus surgery: a recurrence analysis, Ann. Otol. Rhinol. Laryngol., 120, 162, 10.1177/000348941112000304 · DOI · Paper page
- Möller, 2013, Topical drug delivery in chronic rhinosinusitis patients before and after sinus surgery using pulsating aerosols, PLoS One, 8, 10.1371/journal.pone.0074991 · DOI
- Harvey, 2008, Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation, Otolaryngol. Head Neck Surg., 139, 137, 10.1016/j.otohns.2008.04.020 · DOI · Paper page
- Möller, 2014, Drug delivery to paranasal sinuses using pulsating aerosols, J. Aerosol Med. Pulm., 27, 255, 10.1089/jamp.2013.1071 · DOI
- Torres, 2019, Natural polysaccharide nanomaterials: an overview of their immunological properties, Int. J. Mol. Sci., 20, 5092, 10.3390/ijms20205092 · DOI · Paper page
- Klemm, 2005, Cellulose: fascinating biopolymer and sustainable raw material, Angew Chem. Int. Ed. Engl., 44, 3358, 10.1002/anie.200460587 · DOI · Paper page
- Massey, 2016, Biomaterials in rhinology, Otolaryngol. Head Neck Surg., 154, 606, 10.1177/0194599815627782 · doi:10.1177/0194599815627782
- Arca, 2018, Pharmaceutical applications of cellulose ethers and cellulose ether esters, Biomacromolecules, 19, 2351, 10.1021/acs.biomac.8b00517 · doi:10.1021/acs.biomac.8b00517
- Xu, 2012, Hyaluronic acid-based hydrogels: from a natural polysaccharide to complex networks, Soft Matter, 8, 3280, 10.1039/c2sm06463d · DOI · Paper page
- Casale, 2015, Hyaluronic acid: perspectives in upper aero-digestive tract. A systematic review, PLoS One, 10, 1, 10.1371/journal.pone.0130637 · DOI · Paper page
- Hwang, 2018, Randomized controlled trial of steroid-soaked absorbable calcium alginate nasal packing following endoscopic sinus surgery, Laryngoscope, 128, 311, 10.1002/lary.26871 · DOI
- Martău, 2019, The use of chitosan, alginate, and pectin in the biomedical and food sector-biocompatibility, bioadhesiveness, and biodegradability, Polym. Bull., 11, 1837
- Tønnesen, 2002, Alginate in drug delivery systems, Drug Dev. Ind. Pharm., 28, 621, 10.1081/DDC-120003853 · DOI · Paper page
- Abruzzo, 2019, Cromolyn-crosslinked chitosan nanoparticles for the treatment of allergic rhinitis, Eur. J. Pharmaceut. Sci., 131, 136, 10.1016/j.ejps.2019.02.015 · DOI
- Sun, 2019, Nasal adaptive chitosan-based nano-vehicles for anti-allergic drug delivery, Int. J. Biol. Macromol., 135, 1182, 10.1016/j.ijbiomac.2019.05.188 · DOI
- Pandey, 2016, Formulation and evaluation of levocetirizine loaded mucoadhesive microspheres for nasal delivery, Int. J. Pharma Sci. Res., 7, 2242
- Wang, 2020, Astragalus polysaccharides/chitosan microspheres for nasal delivery: preparation, optimization, characterization, and pharmacodynamics, Front. Pharmacol., 11, 230, 10.3389/fphar.2020.00230 · DOI
- Cao, 2015, Potential application of injectable chitosan hydrogel treated with siRNA in chronic rhinosinusitis therapy, Mol. Med. Rep., 12, 6688, 10.3892/mmr.2015.4237 · DOI
- Garakani, 2020, Fabrication of chitosan/polyvinylpyrrolidone hydrogel scaffolds containing PLGA microparticles loaded with dexamethasone for biomedical applications, Int. J. Biol. Macromol., 164, 356, 10.1016/j.ijbiomac.2020.07.138 · DOI
- Su, 2020, Chitosan hydrogel doped with PEG-PLA nanoparticles for the local delivery of miRNA-146a to treat allergic rhinitis, Pharm. Times, 12, 907
- Ways, 2018, Chitosan and its derivatives for application in mucoadhesive drug delivery systems, Polym. Bull., 10, 267
- England, 1999, Nasal pH measurement: a reliable and repeatable parameter, Clin. Otolaryngol. (Oxf.), 24, 67, 10.1046/j.1365-2273.1999.00223.x · DOI · Paper page
- Kim, 2013, Nasal pH in patients with chronic rhinosinusitis before and after endoscopic sinus surgery, Am. J. Otolaryngol., 34, 505, 10.1016/j.amjoto.2013.04.015 · DOI
- Cao, 2009, In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate, Int. J. Pharm., 365, 109, 10.1016/j.ijpharm.2008.08.042 · DOI
- Nižić, 2019, Innovative sprayable in situ gelling fluticasone suspension: development and optimization of nasal deposition, Int. J. Pharm., 563, 445, 10.1016/j.ijpharm.2019.04.015 · DOI
- Gohel, 2009, Preparation and evaluation of soft gellan gum gel containing paracetamol, Indian J. Pharmaceut. Sci., 71, 120, 10.4103/0250-474X.54273 · doi:10.4103/0250-474x.54273
- Bacelar, 2016, Recent progress in gellan gum hydrogels provided by functionalization strategies, J. Mater. Chem. B, 4, 6164, 10.1039/C6TB01488G · DOI · Paper page
- Thakur, 1997, Chemistry and uses of pectin — a review, Crit Rev Food Sci, 37, 47, 10.1080/10408399709527767 · DOI · Paper page
- Adriaensen, 2017, Safety and efficacy of a bioabsorbable fluticasone propionate–eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial, Int. Forum Allergy Rhinol., 7, 813, 10.1002/alr.21963 · doi:10.1002/alr.21963
- Sow, 2018, Pilot study comparing steroid-impregnated and non- steroid-impregnated absorbable nasal dressing following endoscopic sinus surgery, Med. J. Malaysia, 73, 244
- Rajangam, 2013, Fibrinogen and fibrin based micro and nano scaffolds incorporated with drugs, proteins, cells and genes for therapeutic biomedical applications, Int. J. Nanomed., 8, 3641
- Weisel, 2017, Fibrin formation, structure and properties, Subcell. Biochem., 82, 405, 10.1007/978-3-319-49674-0_13 · DOI · Paper page
- Catoira, 2019, Overview of natural hydrogels for regenerative medicine applications, J. Mater. Sci. Mater. Med., 30, 115, 10.1007/s10856-019-6318-7 · DOI · Paper page
- Tyler, 2016, Polylactic acid (PLA) controlled delivery carriers for biomedical applications, Adv. Drug Deliv. Rev., 107, 163, 10.1016/j.addr.2016.06.018 · DOI · Paper page
- Anderson, 2012, Biodegradation and biocompatibility of PLA and PLGA microspheres, Adv. Drug Deliv. Rev., 64, 72, 10.1016/j.addr.2012.09.004 · DOI · Paper page
- Rothstein, 2009, A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices, Biomaterials, 30, 1657, 10.1016/j.biomaterials.2008.12.002 · DOI · Paper page
- Rothstein, 2011, A “tool box” for rational design of degradable controlled release formulations, J. Mater. Chem., 21, 29, 10.1039/C0JM01668C · DOI
- Seyednejad, 2011, Functional aliphatic polyesters for biomedical and pharmaceutical applications, J. Contr. Release, 152, 168, 10.1016/j.jconrel.2010.12.016 · DOI · Paper page
- Dash, 2012, Poly-є-caprolactone based formulations for drug delivery and tissue engineering: a review, J. Contr. Release, 158, 15, 10.1016/j.jconrel.2011.09.064 · DOI · Paper page
- Sharma, 2018, The development of bioresorbable composite polymeric implants with high mechanical strength, Nat. Mater., 17, 96, 10.1038/nmat5016 · DOI · Paper page
- Herzberger, 2016, Polymerization of ethylene oxide, propylene oxide, and other alkylene oxides: synthesis, novel polymer architectures, and bioconjugation, Chem. Rev., 116, 2170, 10.1021/acs.chemrev.5b00441 · DOI · Paper page
- Knop, 2010, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew Chem. Int. Ed. Engl., 49, 6288, 10.1002/anie.200902672 · DOI · Paper page
- Lin, 2009, PEG hydrogels for the controlled release of biomolecules in regenerative medicine, Pharmaceut. Res., 26, 631, 10.1007/s11095-008-9801-2 · DOI · Paper page
- Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
- Giuliano, 2018, Mucosal applications of poloxamer 407-based hydrogels: an overview, Pharm. Times, 10, 159
- Russo, 2019, Poloxamer hydrogels for biomedical applications, Pharm. Times, 11, 671
- Bellotti, 2019, Tuning of thermoresponsive pNIPAAm hydrogels for the topical retention of controlled release ocular therapeutics, J. Mater. Chem. B, 7, 1276, 10.1039/C8TB02976H · DOI
- Klouda, 2008, Thermoresponsive hydrogels in biomedical applications, Eur. J. Pharm. Biopharm., 68, 34, 10.1016/j.ejpb.2007.02.025 · DOI · Paper page
- Lanzalaco, 2017, Poly(N-isopropylacrylamide) and copolymers: a review on recent progresses in biomedical applications, Prog. Colloid Polym. Sci. S, 3, 36
- Cherng, 2013, Polyurethane-based drug delivery systems, Int. J. Pharm., 450, 145, 10.1016/j.ijpharm.2013.04.063 · DOI · Paper page
- Shi, 2009, Recent advances in synthetic bioelastomers, Int. J. Mol. Sci., 10, 4223, 10.3390/ijms10104223 · DOI
- Baker, 2012, A review of polyvinyl alcohol and its uses in cartilage and orthopedic applications, J. Biomed. Mater. Res. B Appl. Biomater., 100B, 1451, 10.1002/jbm.b.32694 · DOI · Paper page
- Franco, 2020, The use of poly(N-vinyl pyrrolidone) in the delivery of drugs: a review, Polym. Bull., 12, 1114
- Ludmila, 2017, PVP based materials: biodegradation in different environments, Ecol. Chem. Eng., 24, 299
- Attama, 2016, Functional performance of chitosan/carbopol 974P NF matrices in captopril tablets, J. Pharm. (Lahore), 2016, 3240290
- Poscher, 2020, Trends in degradable mesoporous organosilica-based nanomaterials for controlling drug delivery: a mini review, Materials, 13, 3668, 10.3390/ma13173668 · DOI
- Jaganathan, 2012, Biocompatibility assessment of Si-based nano- and micro-particles, Adv. Drug Deliv. Rev., 64, 1800, 10.1016/j.addr.2012.05.008 · DOI
- Dkhar, 2018, Intranasal drug delivery devices and interventions associated with post-operative endoscopic sinus surgery, Pharmaceut. Dev. Technol., 23, 282, 10.1080/10837450.2017.1389956 · DOI
- Szczygielski, 2010, Use of CMC foam sinus dressing in FESS, Eur. Arch. Oto-Rhino-Laryngol., 267, 537, 10.1007/s00405-009-1117-2 · DOI
- Rudmik, 2012, Effect of a dexamethasone Sinu-FoamTM middle meatal spacer on endoscopic sinus surgery outcomes: a randomized, double-blind, placebo-controlled trial, Int. Forum Allergy Rhinol., 2, 248, 10.1002/alr.21011 · doi:10.1002/alr.21011
- Patel, 2017, Biocompatibility and pharmacokinetics of fluticasone-eluting sinus implant in a rabbit model, Am. J. Rhinol. Allergy, 31, 382, 10.2500/ajra.2017.31.4481 · doi:10.2500/ajra.2017.31.4481
- Xu, 2016, Absorbable steroid-impregnated spacer after endoscopic sinus surgery to reduce synechiae formation, Ann. Otol. Rhinol. Laryngol., 125, 195, 10.1177/0003489415606446 · DOI
- Côté, 2010, Triamcinolone-impregnated nasal dressing following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study, Laryngoscope, 120, 1269, 10.1002/lary.20905 · doi:10.1002/lary.20905
- Dautremont, 2014, The role of immediate postoperative systemic corticosteroids when utilizing a steroid-eluting spacer following sinus surgery, Otolaryngol. Head Neck Surg., 150, 689, 10.1177/0194599814521373 · DOI
- Zhao, 2018, Effects of mometasone furoate–impregnated biodegradable nasal dressing on endoscopic appearance in healing process following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study, Int. Forum Allergy Rhinol., 8, 1233, 10.1002/alr.22213 · doi:10.1002/alr.22213
- Sabarinath, 2017, Triamcinolone impregnated nasal pack in endoscopic sinus surgery: our experience, Indian J. Otolaryngol., 69, 88, 10.1007/s12070-016-1041-x · DOI
- Zhao, 2013, A systematic review of nonabsorbable, absorbable, and steroid-impregnated spacers following endoscopic sinus surgery, Int. Forum Allergy Rhinol., 3, 896, 10.1002/alr.21201 · doi:10.1002/alr.21201
- Wang, 2014, Merocel versus nasopore for nasal packing: a meta-analysis of randomized controlled trials, PLoS One, 9
- Li, 2019, Efficacy and safety of steroid-impregnated implants following sinus surgery: a meta-analysis, Laryngoscope, 130, 2754, 10.1002/lary.28388 · DOI
- Maccabee, 2003, Effects of topically applied biomaterials on paranasal sinus mucosal healing, Am. J. Rhinol. Allergy, 17, 203, 10.1177/194589240301700405 · doi:10.1177/194589240301700405
- Orlandi, 2004, Is nasal packing necessary following endoscopic sinus surgery?, Laryngoscope, 114, 1541, 10.1097/00005537-200409000-00007 · DOI
- Wei, 2012, Mometasone implant for chronic rhinosinusitis, Med. Devices, 5, 75
- Han, 2019, Topical therapies for management of chronic rhinosinusitis: steroid implants, Int. Forum Allergy Rhinol., 9, S22, 10.1002/alr.22344 · doi:10.1002/alr.22344
- Shen, 2018, Mometasone furoate sinus implant – a new targeted approach to treating recurrent nasal polyp disease, Expet Rev. Clin. Pharmacol., 11, 1163, 10.1080/17512433.2018.1549485 · doi:10.1080/17512433.2018.1549485
- Murr, 2011, Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent, Int. Forum Allergy Rhinol., 1, 23, 10.1002/alr.20020 · DOI · Paper page
- Han, 2014, RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis, Int. Forum Allergy Rhinol., 4, 861, 10.1002/alr.21426 · DOI
- Santarelli, 2016, Evaluation of the PROPEL® mini sinus implant for the treatment of frontal sinus disease, Expet Opin. Drug Deliv., 13, 1789, 10.1080/17425247.2016.1250740 · doi:10.1080/17425247.2016.1250740
- Smith, 2016, Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening, Laryngoscope, 126, 2659, 10.1002/lary.26140 · DOI
- Luong, 2018, Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial, JAMA Otolaryngol Head Neck Surg, 144, 28
- Matheny, 2014, Safety, feasibility, and efficacy of placement of steroid-eluting bioabsorbable sinus implants in the office setting: a prospective case series, Int. Forum Allergy Rhinol., 4, 808, 10.1002/alr.21416 · DOI
- Forwith, 2011, ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants, Laryngoscope, 121, 2473, 10.1002/lary.22228 · DOI
- Kern, 2018, A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps, Int. Forum Allergy Rhinol., 8, 471, 10.1002/alr.22084 · DOI
- Forwith, 2016, RESOLVE: bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis after sinus surgery: 6-month outcomes from a randomized, controlled, blinded study, Int. Forum Allergy Rhinol., 6, 573, 10.1002/alr.21741 · DOI
- Cho, 2017, Tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent in a preclinical model, Int. Forum Allergy Rhinol., 7, 352, 10.1002/alr.21892 · DOI
- Cho, 2018, Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis, Int. Forum Allergy Rhinol., 8, 482, 10.1002/alr.22081 · DOI
- Douglas, 2019, Phase 1 clinical study to assess the safety of a novel drug delivery system providing long-term topical steroid therapy for chronic rhinosinusitis, Int. Forum Allergy Rhinol., 9, 378, 10.1002/alr.22288 · DOI
- Marple, 2012, Advance II: a prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants, Otolaryngol. Head Neck Surg., 146, 1004, 10.1177/0194599811435968 · DOI
- Lavigne, 2014, Steroid-eluting sinus implant for in-office treatment of recurrent nasal polyposis: a prospective, multicenter study, Int. Forum Allergy Rhinol., 4, 381, 10.1002/alr.21309 · DOI
- Al-Halifa, 2019, Nanoparticle-based vaccines against respiratory viruses, Front. Immunol., 10, 22, 10.3389/fimmu.2019.00022 · DOI · Paper page
- Far, 2020, Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery, ACS Omega, 5, 7432, 10.1021/acsomega.0c00111 · doi:10.1021/acsomega.0c00111
- Sallam, 2016, Rationally designed nanocarriers for intranasal therapy of allergic rhinitis: influence of carrier type on in vivo nasal deposition, Int. J. Nanomed., 11, 2345, 10.2147/IJN.S98547 · DOI
- Lai, 2011, Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus, Biomaterials, 32, 6285, 10.1016/j.biomaterials.2011.05.008 · DOI
- Lee, 2017, Sinonasal delivery of resveratrol via mucoadhesive nanostructured microparticles in a nasal polyp mouse model, Sci Rep-Uk, 7, 40249, 10.1038/srep40249 · DOI
- Zheng, 2020, A review of the pharmacological action of Astragalus polysaccharide, Front. Pharmacol., 11, 349, 10.3389/fphar.2020.00349 · doi:10.3389/fphar.2020.00349
- Kim, 2014, Budesonide/cyclodextrin complex-loaded lyophilized microparticles for intranasal application, Drug Dev. Ind. Pharm., 40, 743, 10.3109/03639045.2013.782503 · DOI
- Shi, 2016, The effects of mPEG proportion and LA/GA ratio on degradation and drug release behaviors of PLGA-mPEG microparticles, Pharmazie, 71, 243
- Abuzeid, 2018, Nitric oxide-releasing microparticles as a potent antimicrobial therapeutic against chronic rhinosinusitis bacterial isolates, Int. Forum Allergy Rhinol., 8, 1190, 10.1002/alr.22185 · DOI
- Yang, 2020, Novel nitric oxide‒generating platform using manuka honey as an anti-biofilm strategy in chronic rhinosinusitis, International Forum of Allergy & Rhinology, 10, 223, 10.1002/alr.22472 · DOI
- Lai, 2011, Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus, Biomaterials, 32, 6285, 10.1016/j.biomaterials.2011.05.008 · DOI
- Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI · Paper page
- Kammona, 2012, Recent advances in nanocarrier-based mucosal delivery of biomolecules, J. Contr. Release, 161, 781, 10.1016/j.jconrel.2012.05.040 · DOI
- Mahdi, 2015, Development of mucoadhesive sprayable gellan gum fluid gels, Int. J. Pharm., 488, 12, 10.1016/j.ijpharm.2015.04.011 · DOI
- Altuntaş, 2017, Formulation and evaluation of thermoreversible in situ nasal gels containing mometasone furoate for allergic rhinitis, AAPS PharmSciTech, 18, 2673, 10.1208/s12249-017-0747-8 · doi:10.1208/s12249-017-0747-8
- Karavasili, 2016, Smart materials: in situ gel-forming systems for nasal delivery, Drug Discov. Today, 21, 157, 10.1016/j.drudis.2015.10.016 · DOI · Paper page
- Agrawal, 2020, Stimuli-responsive in situ gelling system for nose-to-brain drug delivery, J. Contr. Release, 327, 235, 10.1016/j.jconrel.2020.07.044 · DOI · Paper page
- Bellotti, 2021, Injectable thermoresponsive hydrogels as drug delivery system for the treatment of central nervous system disorders: a review, J. Contr. Release, 329, 16, 10.1016/j.jconrel.2020.11.049 · DOI · Paper page
- Altuntaş, 2018, Effects of a thermosensitive in situ gel containing mometasone furoate on a rat allergic rhinitis model, Am. J. Rhinol. Allergy, 32, 132, 10.1177/1945892418764951 · doi:10.1177/1945892418764951
- Aksoy, 2017, Effect of a combination of mometasone furoate, levofloxacin, and retinyl palmitate with an in situ gel-forming nasal delivery system on nasal mucosa damage repair in an experimental rabbit model, Biomed. Pharmacother., 96, 603, 10.1016/j.biopha.2017.10.023 · DOI
- Pandey, 2017, Formulation, functional evaluation and ex vivo performance of thermoresponsive soluble gels - a platform for therapeutic delivery to mucosal sinus tissue, Eur. J. Pharmaceut. Sci., 96, 499, 10.1016/j.ejps.2016.10.017 · DOI
- Chu, 2013, Preparation of a paeonol-containing temperature-sensitive in situ gel and its preliminary efficacy on allergic rhinitis, Int. J. Mol. Sci., 14, 6499, 10.3390/ijms14036499 · doi:10.3390/ijms14036499
- Cho, 2019, In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms, Int. Forum Allergy Rhinol., 9, 486, 10.1002/alr.22285 · doi:10.1002/alr.22285
- Lim, 2020, Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis, Int. Forum Allergy Rhinol., 10, 481, 10.1002/alr.22514 · DOI
- Chen, 2020, Injectable and self-healing hydrogel with anti-bacterial and anti-inflammatory properties for acute bacterial rhinosinusitis with micro invasive treatment, Adv Healthc Mater, 9, 2001032, 10.1002/adhm.202001032 · DOI
- Schilling, 2021, A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses, J. Contr. Release, 330, 889, 10.1016/j.jconrel.2020.10.062 · DOI · Paper page
- Gadkaree, 2019, Use of corticosteroid-eluting sinus stents between 2012 and 2017, JAMA Otolaryngol Head Neck Surg, 145, 90, 10.1001/jamaoto.2018.2944 · doi:10.1001/jamaoto.2018.2944
- Rudmik, 2014, Economic evaluation of a steroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis, Otolaryngol. Head Neck Surg., 151, 359, 10.1177/0194599814533779 · DOI
- Li, 2020, Design of biodegradable, implantable devices towards clinical translation, Nat. Rev. Mater., 5, 61, 10.1038/s41578-019-0150-z · DOI · Paper page
- Salade, 2019, How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods, Int. J. Pharm., 561, 47, 10.1016/j.ijpharm.2019.02.026 · DOI
- Al-Sayed, 2017, Models for the study of nasal and sinus physiology in health and disease: a review of the literature, Laryngoscope Investig Otolaryngol, 2, 398, 10.1002/lio2.117 · DOI
- Schilling, 2021, Evaluating inflammation in an obstruction-based chronic rhinosinusitis model in rabbits, Int. Forum Allergy Rhinol., 11, 807, 10.1002/alr.22729 · doi:10.1002/alr.22729
- Cho, 2020, A preclinical model to tackle chronic rhinosinusitis, Int. Forum Allergy Rhinol.
- Schilling, 2021, Reply: a preclinical model to tackle chronic rhinosinusitis, Int. Forum Allergy Rhinol., 11, 828, 10.1002/alr.22769 · doi:10.1002/alr.22769
Cited by
Yathavan, B., Chhibber, T., Steinhauff, D., Pulsipher, A., Alt, J. A., Ghandehari, H., & Jafari, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102426 · Cited by 20
Metadata
- Authors
- Schilling, A. L., Cannon, E., Lee, S. E., Wang, E. W., & Little, S. R.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 282
- Pages
- 121430
- ISSN
- 0142-9612
- Cited by
- 30
- References
- 6
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Eye and Ear Foundation of Pittsburgh
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in controlled drug delivery to the sinonasal mucosa. https://app.cochat.ai/papers/10.1016/j.biomaterials.2022.121430
- The paper
- Schilling, A. L., Cannon, E., Lee, S. E., Wang, E. W., & Little, S. R. (2022). Advances in controlled drug delivery to the sinonasal mucosa. Biomaterials. https://doi.org/10.1016/j.biomaterials.2022.121430
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.